CA2766210A1 - Single nucleotide polymorphisms in brca1 and cancer risk - Google Patents
Single nucleotide polymorphisms in brca1 and cancer risk Download PDFInfo
- Publication number
- CA2766210A1 CA2766210A1 CA2766210A CA2766210A CA2766210A1 CA 2766210 A1 CA2766210 A1 CA 2766210A1 CA 2766210 A CA2766210 A CA 2766210A CA 2766210 A CA2766210 A CA 2766210A CA 2766210 A1 CA2766210 A1 CA 2766210A1
- Authority
- CA
- Canada
- Prior art keywords
- snp
- mirna
- breast
- cancer
- brca1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002773 nucleotide Substances 0.000 title claims abstract description 143
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 143
- 102000054765 polymorphisms of proteins Human genes 0.000 title claims abstract description 37
- 206010028980 Neoplasm Diseases 0.000 title claims description 135
- 201000011510 cancer Diseases 0.000 title claims description 83
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 226
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 223
- 238000000034 method Methods 0.000 claims abstract description 130
- 239000002679 microRNA Substances 0.000 claims abstract description 111
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 58
- 210000000481 breast Anatomy 0.000 claims abstract description 58
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 56
- 230000014509 gene expression Effects 0.000 claims abstract description 55
- 101150072950 BRCA1 gene Proteins 0.000 claims abstract description 31
- 108700040618 BRCA1 Genes Proteins 0.000 claims abstract description 27
- 230000007423 decrease Effects 0.000 claims abstract description 20
- 102000036365 BRCA1 Human genes 0.000 claims abstract description 9
- 108700020463 BRCA1 Proteins 0.000 claims abstract description 9
- 230000004075 alteration Effects 0.000 claims abstract description 7
- 102000054766 genetic haplotypes Human genes 0.000 claims description 243
- 239000000523 sample Substances 0.000 claims description 156
- 108700011259 MicroRNAs Proteins 0.000 claims description 148
- 108020004414 DNA Proteins 0.000 claims description 71
- 102220078036 rs8176318 Human genes 0.000 claims description 59
- 238000012360 testing method Methods 0.000 claims description 46
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 42
- 102220035514 rs1060915 Human genes 0.000 claims description 42
- 102220039367 rs12516 Human genes 0.000 claims description 35
- 108091026890 Coding region Proteins 0.000 claims description 33
- 102220035577 rs3092995 Human genes 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 24
- 108091023818 miR-7 stem-loop Proteins 0.000 claims description 22
- 230000001404 mediated effect Effects 0.000 claims description 12
- 239000013068 control sample Substances 0.000 claims description 11
- 108091023045 Untranslated Region Proteins 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 8
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 7
- 108091092724 Noncoding DNA Proteins 0.000 claims description 6
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 3
- 108091062157 Cis-regulatory element Proteins 0.000 claims description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 2
- 108091029795 Intergenic region Proteins 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 81
- 230000035772 mutation Effects 0.000 abstract description 39
- 108091070501 miRNA Proteins 0.000 abstract description 16
- 230000003247 decreasing effect Effects 0.000 abstract description 6
- 230000004663 cell proliferation Effects 0.000 abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 description 143
- 102000039446 nucleic acids Human genes 0.000 description 129
- 108020004707 nucleic acids Proteins 0.000 description 129
- 101000934870 Homo sapiens Breast cancer type 1 susceptibility protein Proteins 0.000 description 106
- 239000013615 primer Substances 0.000 description 105
- 108700028369 Alleles Proteins 0.000 description 100
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 description 100
- 238000001514 detection method Methods 0.000 description 76
- 108020005345 3' Untranslated Regions Proteins 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 56
- 239000003153 chemical reaction reagent Substances 0.000 description 50
- 201000010099 disease Diseases 0.000 description 40
- 238000003205 genotyping method Methods 0.000 description 40
- 238000003556 assay Methods 0.000 description 39
- 108020004999 messenger RNA Proteins 0.000 description 36
- 102000015694 estrogen receptors Human genes 0.000 description 34
- 108010038795 estrogen receptors Proteins 0.000 description 34
- 238000003752 polymerase chain reaction Methods 0.000 description 32
- 102000040430 polynucleotide Human genes 0.000 description 32
- 108091033319 polynucleotide Proteins 0.000 description 32
- 239000002157 polynucleotide Substances 0.000 description 32
- 102000003998 progesterone receptors Human genes 0.000 description 31
- 108090000468 progesterone receptors Proteins 0.000 description 31
- 238000003199 nucleic acid amplification method Methods 0.000 description 30
- 230000003321 amplification Effects 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 238000009396 hybridization Methods 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- 210000000349 chromosome Anatomy 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 24
- 230000002068 genetic effect Effects 0.000 description 24
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 22
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 22
- 108091034117 Oligonucleotide Proteins 0.000 description 21
- 239000000975 dye Substances 0.000 description 21
- 239000002987 primer (paints) Substances 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 239000012634 fragment Substances 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 108091093037 Peptide nucleic acid Proteins 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- 238000003491 array Methods 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 15
- 230000000875 corresponding effect Effects 0.000 description 14
- 238000004949 mass spectrometry Methods 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 238000012163 sequencing technique Methods 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 10
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000022131 cell cycle Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 7
- 238000003499 nucleic acid array Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 6
- 102000043276 Oncogene Human genes 0.000 description 6
- 108700020796 Oncogene Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000005251 capillar electrophoresis Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 102000048580 human BRCA1 Human genes 0.000 description 6
- 239000002751 oligonucleotide probe Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 230000002974 pharmacogenomic effect Effects 0.000 description 5
- 201000010700 sporadic breast cancer Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 208000030555 Pygmy Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000002032 lab-on-a-chip Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108091033380 Coding strand Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 102000048850 Neoplasm Genes Human genes 0.000 description 3
- 108700019961 Neoplasm Genes Proteins 0.000 description 3
- 102100037001 Next to BRCA1 gene 1 protein Human genes 0.000 description 3
- 238000002944 PCR assay Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282575 Gorilla Species 0.000 description 2
- 108091061618 Homo sapiens miR-637 stem-loop Proteins 0.000 description 2
- 101150017040 I gene Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000282576 Pan paniscus Species 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 241000364051 Pima Species 0.000 description 2
- 241000282405 Pongo abelii Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000007844 allele-specific PCR Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 238000012098 association analyses Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108091026955 miR-1180 stem-loop Proteins 0.000 description 2
- -1 miR-146-5p Proteins 0.000 description 2
- 108091072763 miR-151 stem-loop Proteins 0.000 description 2
- 108091046933 miR-18b stem-loop Proteins 0.000 description 2
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000037230 mobility Effects 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102000037983 regulatory factors Human genes 0.000 description 2
- 108091008025 regulatory factors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000037426 transcriptional repression Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000000225 tumor suppressor protein Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000005749 Anthriscus sylvestris Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000051618 BRCA1-associated protein Human genes 0.000 description 1
- 108700039023 BRCA1-associated protein Proteins 0.000 description 1
- 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical group C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 244000062327 Eupatorium odoratum Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000047351 Exportin-5 Human genes 0.000 description 1
- 101100112369 Fasciola hepatica Cat-1 gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100028701 General vesicular transport factor p115 Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 208000033640 Hereditary breast cancer Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000847058 Homo sapiens Exportin-5 Proteins 0.000 description 1
- 101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 description 1
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 1
- 101000690100 Homo sapiens U1 small nuclear ribonucleoprotein 70 kDa Proteins 0.000 description 1
- 108091067642 Homo sapiens miR-129-1 stem-loop Proteins 0.000 description 1
- 108091069093 Homo sapiens miR-129-2 stem-loop Proteins 0.000 description 1
- 108091068954 Homo sapiens miR-185 stem-loop Proteins 0.000 description 1
- 108091086636 Homo sapiens miR-298 stem-loop Proteins 0.000 description 1
- 108091067007 Homo sapiens miR-324 stem-loop Proteins 0.000 description 1
- 108091053842 Homo sapiens miR-412 stem-loop Proteins 0.000 description 1
- 108091061677 Homo sapiens miR-654 stem-loop Proteins 0.000 description 1
- 108091060481 Homo sapiens miR-758 stem-loop Proteins 0.000 description 1
- 241000282597 Hylobates Species 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 239000006131 Keralite Substances 0.000 description 1
- 235000009199 Lamium album Nutrition 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 244000245214 Mentha canadensis Species 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 102000010645 MutS Proteins Human genes 0.000 description 1
- 108010038272 MutS Proteins Proteins 0.000 description 1
- 101100005271 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-1 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241001018696 Quechua Species 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 208000033722 Rare malignant breast tumor Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 241000198381 Rondonia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000512294 Thais Species 0.000 description 1
- 108010087298 Tn receptor Proteins 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100024121 U1 small nuclear ribonucleoprotein 70 kDa Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 101150090192 how gene Proteins 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000000504 luminescence detection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 108091041042 miR-18 stem-loop Proteins 0.000 description 1
- 108091062221 miR-18a stem-loop Proteins 0.000 description 1
- 108091038080 miR-18a-1 stem-loop Proteins 0.000 description 1
- 108091050874 miR-19a stem-loop Proteins 0.000 description 1
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 description 1
- 108091037787 miR-19b stem-loop Proteins 0.000 description 1
- 108091028067 miR-19b-1 stem-loop Proteins 0.000 description 1
- 108091048308 miR-210 stem-loop Proteins 0.000 description 1
- 108091068829 miR-210-1 stem-loop Proteins 0.000 description 1
- 108091039812 miR-28 stem-loop Proteins 0.000 description 1
- 108091055145 miR-342 stem-loop Proteins 0.000 description 1
- 108091030670 miR-365 stem-loop Proteins 0.000 description 1
- 108091043604 miR-365-1 stem-loop Proteins 0.000 description 1
- 108091036688 miR-365-3 stem-loop Proteins 0.000 description 1
- 108091037014 miR-7-1 stem-loop Proteins 0.000 description 1
- 108091007426 microRNA precursor Proteins 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Chemical group 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108091007428 primary miRNA Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000003201 single nucleotide polymorphism genotyping Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 239000006226 wash reagent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22034209P | 2009-06-25 | 2009-06-25 | |
| US61/220,342 | 2009-06-25 | ||
| PCT/US2010/040105 WO2010151841A2 (en) | 2009-06-25 | 2010-06-25 | Single nucleotide polymorphisms in brca1 and cancer risk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2766210A1 true CA2766210A1 (en) | 2010-12-29 |
Family
ID=43013251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2766210A Abandoned CA2766210A1 (en) | 2009-06-25 | 2010-06-25 | Single nucleotide polymorphisms in brca1 and cancer risk |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20120156676A1 (enExample) |
| EP (1) | EP2446056A2 (enExample) |
| JP (1) | JP2012531210A (enExample) |
| CN (1) | CN102575289A (enExample) |
| AU (1) | AU2010265889A1 (enExample) |
| CA (1) | CA2766210A1 (enExample) |
| IL (1) | IL217120A0 (enExample) |
| WO (1) | WO2010151841A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013168162A1 (en) * | 2012-05-09 | 2013-11-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Clustered single nucleotide polymorphisms in the human acetylcholinesterase gene and uses thereof in diagnosis and therapy |
| CN102994512B (zh) * | 2012-11-16 | 2014-08-13 | 山东大学齐鲁医院 | 一种用于检测卵巢癌易感性的分子标记、试剂盒及其检测方法 |
| GB201403820D0 (en) * | 2014-03-04 | 2014-04-16 | Isis Innovation | Assay |
| US9710451B2 (en) * | 2014-06-30 | 2017-07-18 | International Business Machines Corporation | Natural-language processing based on DNA computing |
| CN104178567B (zh) * | 2014-07-22 | 2016-01-20 | 南京医科大学 | 一种与乳腺癌辅助诊断相关的snp标志物及其应用 |
| IL251376B (en) * | 2014-09-30 | 2022-09-01 | Genetic Tech Limited | Methods for assessing risk of developing breast cancer |
| EP3916106A1 (en) * | 2015-03-09 | 2021-12-01 | Agency for Science, Technology and Research | Method of determining the risk of developing breast cancer |
| CA2980078C (en) * | 2015-03-16 | 2024-03-12 | Personal Genome Diagnostics Inc. | Systems and methods for analyzing nucleic acid |
| US10388404B2 (en) | 2015-10-27 | 2019-08-20 | International Business Machines Corporation | Using machine-learning to perform linear regression on a DNA-computing platform |
| TWI617668B (zh) * | 2017-03-15 | 2018-03-11 | Carcinoma risk assessment method | |
| WO2019074933A2 (en) * | 2017-10-10 | 2019-04-18 | Nantomics, Llc | COMPLETE GENOMIC TRANSCRIPTOM ANALYSIS OF A PANEL OF NORMAL-TUMOR GENES FOR ENHANCED PRECISION IN PATIENTS WITH CANCER |
| JP7138077B2 (ja) * | 2019-04-23 | 2022-09-15 | ジェネシスヘルスケア株式会社 | 卵巣がん及び／又は子宮がんのリスクを判定する方法 |
| CN110331202A (zh) * | 2019-07-29 | 2019-10-15 | 湖北大学 | 一种用于检测brac1基因snp的试剂盒与方法 |
| EP4332241A1 (en) | 2022-09-01 | 2024-03-06 | Consejo Superior de Investigaciones Cientificas | Single nucleotide polymorphism for the prognosis of breast cancer |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| NO870613L (no) | 1986-03-05 | 1987-09-07 | Molecular Diagnostics Inc | Deteksjon av mikroorganismer i en prve inneholdende nukleinsyre. |
| US5004565A (en) | 1986-07-17 | 1991-04-02 | The Board Of Governors Of Wayne State University | Method and compositions providing enhanced chemiluminescence from 1,2-dioxetanes |
| US5856522A (en) | 1995-05-04 | 1999-01-05 | Tropix, Inc. | Method of using synthesis of 1,2-dioxetanes and kits therefore |
| US4988617A (en) | 1988-03-25 | 1991-01-29 | California Institute Of Technology | Method of detecting a nucleotide change in nucleic acids |
| WO1989010414A1 (en) | 1988-04-28 | 1989-11-02 | Robert Bruce Wallace | AMPLIFIED SEQUENCE POLYMORPHISMS (ASPs) |
| EP0451141B1 (en) | 1988-05-20 | 1998-11-18 | F. Hoffmann-La Roche Ag | Immobilized sequence-specific probes |
| US4988167A (en) | 1988-08-10 | 1991-01-29 | Fergason James L | Light blocking and vision restoration apparatus with glint control |
| US5118801A (en) | 1988-09-30 | 1992-06-02 | The Public Health Research Institute | Nucleic acid process containing improved molecular switch |
| JP3021036B2 (ja) | 1989-02-13 | 2000-03-15 | ジェネコ・ピーティーワイ・リミテッド | 核酸配列又はその中の変化の検出 |
| CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5302509A (en) | 1989-08-14 | 1994-04-12 | Beckman Instruments, Inc. | Method for sequencing polynucleotides |
| US5494810A (en) | 1990-05-03 | 1996-02-27 | Cornell Research Foundation, Inc. | Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5994073A (en) | 1990-08-30 | 1999-11-30 | Tropix, Inc. | Enhancement of chemiluminescent assays |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5270184A (en) | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
| EP0655090B1 (en) | 1992-04-27 | 2000-12-27 | The Trustees Of Dartmouth College | Detection of gene sequences in biological fluids |
| DE69433811T2 (de) | 1993-01-07 | 2005-06-23 | Sequenom, Inc., San Diego | Dns - sequenzierung durch massenspektronomie |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US5422252A (en) | 1993-06-04 | 1995-06-06 | Becton, Dickinson And Company | Simultaneous amplification of multiple targets |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US6027923A (en) | 1993-07-23 | 2000-02-22 | Bio-Rad Laboratories, Inc. | Linked linear amplification of nucleic acids |
| US5527675A (en) | 1993-08-20 | 1996-06-18 | Millipore Corporation | Method for degradation and sequencing of polymers which sequentially eliminate terminal residues |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| DE4331012A1 (de) | 1993-09-13 | 1995-03-16 | Bayer Ag | Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik |
| AU8126694A (en) | 1993-10-26 | 1995-05-22 | Affymax Technologies N.V. | Arrays of nucleic acid probes on biological chips |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| IL108159A (en) | 1993-12-23 | 1998-02-08 | Orgenics Ltd | Apparatus for separation, concentration and detection of target molecules in liquid sample |
| WO1995021271A1 (en) | 1994-02-07 | 1995-08-10 | Molecular Tool, Inc. | Ligase/polymerase-mediated genetic bit analysistm of single nucleotide polymorphisms and its use in genetic analysis |
| US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5705333A (en) | 1994-08-05 | 1998-01-06 | The Regents Of The University Of California | Peptide-based nucleic acid mimics(PENAMS) |
| US5773628A (en) | 1994-11-14 | 1998-06-30 | Tropix, Inc. | 1,2-dioxetane compounds with haloalkoxy groups, methods preparation and use |
| US5591591A (en) | 1995-02-09 | 1997-01-07 | Tropix, Inc. | Dioxetane compounds for the chemiluminescent detection of proteases, methods of use and kits therefore |
| US5589136A (en) | 1995-06-20 | 1996-12-31 | Regents Of The University Of California | Silicon-based sleeve devices for chemical reactions |
| US5801115A (en) | 1995-09-05 | 1998-09-01 | Kataleuna Gmbh | Catalyst composition and methods for using and preparing same |
| US5679803A (en) | 1995-10-25 | 1997-10-21 | Tropix, Inc. | 1,2 chemiluminescent dioxetanes of improved performance |
| US5945283A (en) | 1995-12-18 | 1999-08-31 | Washington University | Methods and kits for nucleic acid analysis using fluorescence resonance energy transfer |
| EP2368897B1 (en) | 1996-02-09 | 2016-10-19 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| US5885470A (en) | 1997-04-14 | 1999-03-23 | Caliper Technologies Corporation | Controlled fluid transport in microfabricated polymeric substrates |
| EP2369007B1 (en) | 1996-05-29 | 2015-07-29 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| US5866336A (en) | 1996-07-16 | 1999-02-02 | Oncor, Inc. | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US6117635A (en) | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US5800999A (en) | 1996-12-16 | 1998-09-01 | Tropix, Inc. | Dioxetane-precursor-labeled probes and detection assays employing the same |
| KR100351531B1 (ko) | 1997-04-25 | 2002-09-11 | 캘리퍼 테크놀로지스 코포레이션 | 기하형상이 개선된 채널을 채용하는 미소 유체 장치 |
| US6390402B2 (en) | 1998-08-14 | 2002-05-21 | Verbatim Corporation | Tape cartridge having lockout features |
| US6506594B1 (en) | 1999-03-19 | 2003-01-14 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| WO2002072889A2 (en) | 2001-01-12 | 2002-09-19 | Applera Corporation | Methods and compositions for microarray control |
| EP2527472B1 (en) * | 2007-05-31 | 2016-09-28 | Yale University | A genetic lesion associated with cancer |
| WO2009033140A1 (en) * | 2007-09-06 | 2009-03-12 | The Ohio State University Research Foundation | Microrna signatures in human ovarian cancer |
-
2010
- 2010-06-25 WO PCT/US2010/040105 patent/WO2010151841A2/en not_active Ceased
- 2010-06-25 CA CA2766210A patent/CA2766210A1/en not_active Abandoned
- 2010-06-25 CN CN201080037526.7A patent/CN102575289A/zh active Pending
- 2010-06-25 JP JP2012517803A patent/JP2012531210A/ja active Pending
- 2010-06-25 US US13/379,995 patent/US20120156676A1/en not_active Abandoned
- 2010-06-25 AU AU2010265889A patent/AU2010265889A1/en not_active Abandoned
- 2010-06-25 EP EP10727324A patent/EP2446056A2/en not_active Withdrawn
-
2011
- 2011-12-21 IL IL217120A patent/IL217120A0/en unknown
-
2013
- 2013-08-26 US US13/975,983 patent/US20150025230A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120156676A1 (en) | 2012-06-21 |
| JP2012531210A (ja) | 2012-12-10 |
| CN102575289A (zh) | 2012-07-11 |
| WO2010151841A3 (en) | 2011-04-14 |
| US20150025230A1 (en) | 2015-01-22 |
| AU2010265889A1 (en) | 2012-01-19 |
| WO2010151841A2 (en) | 2010-12-29 |
| EP2446056A2 (en) | 2012-05-02 |
| IL217120A0 (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20150025230A1 (en) | Single Nucleotide Polymorphisms in BRCA1 and Cancer Risk | |
| EP2527472B1 (en) | A genetic lesion associated with cancer | |
| AU2008286361B2 (en) | IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease | |
| EP2700723B1 (en) | Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene | |
| US11287425B2 (en) | Genetic markers associated with endometriosis and use thereof | |
| AU2008261970A1 (en) | Genetic markers associated with endometriosis and use thereof | |
| US20200087728A1 (en) | Genetic markers associated with endometriosis and use thereof | |
| JP2007527241A (ja) | 上皮細胞成長因子受容体遺伝子プロモーターにおける多型 | |
| CA2751287A1 (en) | A snp marker of breast and ovarian cancer risk | |
| AU2013276994C1 (en) | IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20150625 |